The United States of America, As Represented by the Secretary, Department of Health and Human Services

Florida State University Research Foundation, Inc.

University of Pennsylvania

University of Kansas

Other

Johns Hopkins University

The Brigham and Women's Hospital, Inc.

Forschungsverbund Berlin E.v.

Northwestern University

Florida International University

Loyola University of Chicago

Scientific Components Corporation

University System of Maryland

University of Houston System

Icahn School of Medicine at Mount Sinai

Wei Ping Zheng

Noel Terrence Southall

Juan Jose Marugan

Wenwei Huang

Khalida Shamim

Miao Xu

Hengli Tang

Ruili Huang

Hongjun Song

Emily M Lee

Samarjit Patnaik

Guoli Ming

Steven Titus

Jingbo Xiao

Philip Edward Sanderson

Xiuli Huang

Craig J Thomas

Frank John Schoenen

James Inglese

Ehud Goldin

Wendy Westbroek

John C McKew

Bruce M Raaka

Susanne Neumann

Marvin C Gershengorn

Gregory J Tawa

Gerd Krause

Gunnar Kleinau

Ellen Sidransky

Hao Li

Arthur Lee

Kevin Frankowski

Paul B Yu

Paresma R Patel

Marc Ferrer-Alegre

Catherine Chen

Christopher P Austin

Omid Motabar

Guo-Li Ming

Asaf Alimardanov

Jian-kang Jiang

Sui Huang

John Thomas Norton

Irina Agoulnik

Kim C Williamson

Radha Setty

Ke Liu

Alexander Agoulnik

Junfeng Huang

Wei Sun

Anil Mathew Tharappel

Hangmao Sun

Xiao Lu

Myunghoon Kim

Meghan J Orr

Igor Lumelskiy

Shu Yang

Gregory D Cuny

Xin Hu

Steven Andrew Rogers

Marc Ferrer

Yiannis A Ioannou

Chen Wang

Patricia Dranchak

Agustin H Mohedas

Kelin Li

Menghang Xia

Zhexing Wen

Elma Aflaki

Pu Liu

Lea Cunningham

Andrey Galkin

Liudmila Kulakova

Osnat Herzberg

Yichen Cheng

Yi Zhou

Mercedes Taylor

Raul Rolando Calvo

Seameen Dehdasthi

Fannie Chen

Tsanyang Liang

Zongyi Hu

Shanshan He

Manju Swaroop

The present invention concerns the use of compounds and compositions for the treatment or prevention of Flavivirus infections, such as dengue virus infections and Zika virus infections. Aspects of the invention include methods for treating or preventing Flavivirus virus infection, such as dengue virus and Zika virus infection, by administering a compound or composition of the invention, to a subject in need thereof; methods for inhibiting Flavivirus infections, such as dengue virus and Zika virus infections, in a cell in vitro or in vivo; pharmaceutical compositions; packaged dosage formulations; and kits useful for treating or preventing Flavivirus infections, such as dengue virus and Zika virus infections.

Method for inhibiting dengue virus infection

Method for inhibiting Zika virus infection

Disclosed are compounds of formula (I) and formula (II): wherein R, R, A, and B are as defined herein. Also disclosed is a method of blocking transmission of aparasite and a method of treating or preventing malaria comprising administering to an animal an effective amount of a first compound of formula (I) or (II) either alone or in combination with a second compound selected from elesclomol, NSC174938, NVP-AUY922, Maduramicin, Narasin, Alvespimycin, Omacetaxine, Thiram, Zinc pyrithione, Phanquinone, Bortezomib, Salinomycin sodium, Monensin sodium, Dipyrithione, Dicyclopentamethylene-thiuram disulfide, YM155, Withaferin A, Adriamycin, Romidepsin, AZD-1152-HQPA, CAY10581, Plicamycin, CUDC-101, Auranofin, Trametinib, GSK-458, Afatinib, and Panobinostat.

Compounds and method for blocking transmission of malarial parasite

The present invention provides small-molecule inhibitors of BMP signaling and compositions and methods for inhibiting BMP signaling. These compounds and compositions may be used to modulate cell growth, differentiation, proliferation, and apoptosis, and thus may be useful for treating diseases or conditions associated with BMP signaling, including inflammation, cardiovascular disease, hematological disease, cancer, and bone disorders, as well as for modulating cellular differentiation and/or proliferation. These compounds and compositions may also be used to treat subjects with Sj&#xf6;gren's syndrome, or diffuse intrinsic pontine glioma (DIPG).

ALK2 inhibitors and methods for inhibiting BMP signaling

Anti-flavivirus compounds and methods of use

The present invention concerns the use of emetine compounds for the treatment or prevention of Flavivirus infections, such as dengue virus infections. Aspects of the invention include methods for treating or preventing Flavivirus virus infection, such as dengue virus infection, by administering an emetine compound such as emetine or cephaeline, or a combination of two or more emetine compounds, to a subject in need thereof; methods for inhibiting Flavivirus infections such as dengue virus infections in a cell in vitro or in vivo; pharmaceutical compositions; packaged dosage formulations; and kits for treating or preventing Flavivirus infections, such dengue virus infections.

Emetine compounds for treatment and prevention of flavivirus infection

The invention provides for methods of treating lysosomal storage disorders and/or reduction of non-cholesterol lipids, using cyclodextrin compounds, including in combination with other therapeutics, including vitamin E.

Cyclodextrin for the treatment of lysosomal storage diseases

Disclosed are compounds of formula (I) and formula (II): (I) (II) wherein R, R, A, and B are as defined herein. Also disclosed is a method of blocking transmission of aparasite and a method of treating or preventing malaria comprising administering to an animal an effective amount of a first compound of formula (I) or (II) either alone or in combination with a second compound selected from elesclomol, NSC174938, NVP-AUY922, Maduramicin, Narasin, Alvespimycin, Omacetaxine, Thiram, Zinc pyrithione, Phanquinone, Bortezomib, Salinomycin sodium, Monensin sodium, Dipyrithione, Dicyclopentamethylene-thiuram disulfide, YM155, Withaferin A, Adriamycin, Romidepsin, AZD-1152-HQPA, CAY10581, Plicamycin, CUDC-101, Auranofin, Trametinib, GSK-458, Afatinib, and Panobinostat. 

The present invention concerns the use of compounds for the treatment or prevention of Flavivirus infections, such as Zika virus infections. Aspects of the invention include methods for treating or preventing Flavivirus virus infection, such as Zika virus infection, by administering a compound or class of compound disclosed herein, such as a niclosamide compound, an emricasan compound, a cyclin-dependent kinase inhibitor, a proteasome inhibitor, or a combination of two or more of the foregoing, to a subject in need thereof; methods for inhibiting Flavivirus infections such as Zika virus infections in a cell in vitro or in vivo; pharmaceutical compositions; packaged dosage formulations; and kits for treating or preventing Flavivirus infections, such Zika virus infections.

Compounds and methods for treatment and prevention of Flavivirus infection

Substituted pyrazolopyrimidines and dihydropyrazolopyrimidines and related compounds, their methods of manufacture, compositions containing these compounds, and methods of use of these compounds in treating lysosomal storage disorders such as Gaucher disease are described herein. The compounds are of general Formula (I) in which variables R-Rand X are described in the application.

Substituted pyrazolopyrimidines as glucocerebrosidase activators

The present invention concerns the use of emetine compounds for the treatment or prevention of Flavivirus infections, such as Zika virus infections. Aspects of the invention include methods for treating or preventing Flavivirus virus infection, such as Zika virus infection, by administering an emetine compound such as emetine or cephaeline, or a combination of two or more emetine compounds, to a subject in need thereof; methods for inhibiting Flavivirus infections such as Zika virus infections in a cell in vitro or in vivo; pharmaceutical compositions; packaged dosage formulations; and kits for treating or preventing Flavivirus infections, such Zika virus infections.

Growing community of inventors

Brooklyn, NY, United States of America

Wei Ping Zheng